Biolytx pharmaceuticals corp
WebView the business profile and contact info for Douglas Branch, Chief Executive Officer at Biolytx Pharmaceuticals Corp. in Oklahoma, US Dynamic search and list-building … WebAddress: 800 Research Pkwy Ste 334 Oklahoma City, OK, 73104-3600 United States
Biolytx pharmaceuticals corp
Did you know?
WebOct 16, 2015 · Biolytx Pharmaceuticals General Information. Description. Developer of peptide-based antibiotics designed to treat serious pathogens with no current therapeutic options. The company's antibiotics include a suite of antimicrobial drug candidates for the treatment of serious pathogens including those resistant to current antibiotics, enabling ... WebBiolytx Pharmaceuticals is a pharmaceutical technology company developed by Dr. Anne Pereira and the University of Oklahoma Health Sciences Center. Still in the pre-clinical trial stage, the company's core technology is the development of a novel antibiotic peptide for use in treatment of serious hospital-acquired infections, including those ...
WebBiolytx Pharmaceuticals Corp. Research Services Oklahoma City, Oklahoma Amethyst Research, Inc. Defense and Space Manufacturing Ardmore, Oklahoma Humanity Hospice, LLC ... WebBiolytx Pharmaceuticals. Drug Stores & Pharmacies · Oklahoma, United States · <25 Employees . Founded in 2005 by H. Anne Pereira, Ph.D., and William A. Hagstrom, Biolytx is a pharmaceutical technology company developing a novel antibiotic peptide for potential use in wound healing and treatment of serious hospital-acquired infections, including …
WebBiolytx Pharmaceuticals. Biolytx is an emerging drug development company confronting the crisis in antibiotic (AB) drug resistance through the advancement of a suite of … Dr. Pereira is the holder of 15 US patents and 4 foreign patents licensed to Biolytx. … The CSO of Biolytx characterized, sequenced, and cloned the peptide and … BP001. BP001 is an antibiotic and wound healing agent for infected eye wounds. … Pre-Clinical Stage. All of our drug candidates are in the pre-clinical stage … INVESTORS We completed a $1.5 million seed round of financing in 2015, led by … Biolytx Pharmaceuticals Targets Drug-Resistant Bacteria March 25 , 2015 – … Biolytx Pharmaceuticals Corporation 800 Research Parkway, Suite Oklahoma … William A Hagstrom Board Member and Co-Founder. Mr. Hagstrom has served as a … WebJul 8, 2015 · Biolytx Pharmaceuticals has a novel new drug developed from a peptide (a small part of a protein) that is created by the human body. ... a nonprofit corporation that mentors many of the state’s technology-based startup companies. i2E receives state appropriations from the Oklahoma Center for the Advancement of Science and Technology.
WebOKLAHOMA CITY, OK — A $500,000 investment from the i2E, Inc.-managed Oklahoma Seed Capital Fund recently led a $1.1 million financing round in Oklahoma City-based …
WebCompany profile page for Biolytx Pharmaceuticals Corp including stock price, company news, press releases, executives, board members, and contact information Skip To … sohn gottesWebBiolytx Pharmaceuticals Corp. is developing a peptide, BP001, derived from the human endogenous host defense protein CAP37, as a novel multi-target ophthalmic product for corneal infections and injuries. The standard-of-care for corneal infections is topical administration of antibiotics that may be accompanied by topical sohn grayson rating scaleWebCherryvale, KS 67335. $16.50 - $17.00 an hour. Full-time. Monday to Friday + 5. Easily apply. Urgently hiring. Training- Days - Monday through Thursday- 6am- 4pm for 2 … sohn fccWebFind company research, competitor information, contact details & financial data for Biolytx Pharmaceuticals Corp. of Oklahoma City, OK. Get the latest business insights from … slpa termination of supervision formWebWilliam A. Hagstrom. Mr. Hagstrom has served as a member of our Board of Directors since incorporation in 2005. He has served as the founder and CEO of Octave Bioscience, an early-stage diagnostics company focused on neurodegenerative diseases since 2014. söhngen online shopWebBiolytx Pharmaceuticals Corp . Profile last edited on: 3/24/2024 CAGE: 7D9G6 UEI: LBXKMFJ5KQA3. Drug for promoting wound healing and killing antibiotic resistant … slp ath phpWebNov 7, 2015 · Biolytx funds raised Biolytx is developing a drug designed to promote wound healing and kill antibiotic resistant bacteria. This latest financing also included $200,000 from i2E-managed SeedStep Angels group, $250,000 from an Oklahoma venture capital fund and $150,000 in investment by Biolytx management. sohn harley